Brexit goes real – What’s next for Pharma and Medtech
On 31 January 2020 (midnight CET), the UK will officially leave the European Union (EU) and enter into a transition period which will last until 31 December 2020, if no extension is requested by the UK and agreed by the EU.
During this transition period, the UK will remain in the EU’s customs union and single market and all rights and obligations of companies and citizens will be unaffected. However, the UK will not be a member of EU institutional organizations eg. EMA and will have no influence on ongoing and future changes.
Negotiations will take place for future trade conditions. The outcomes of these negotiations remain unclear and can range from a Free Trade Agreement/Mutual Recognition Agreement (with full or partial alignment) to the UK dealing with the EU on WTO terms.
MHRA and EU institutions will update their guidelines reflecting outcomes of these political discussions.
SFL has long-standing experience in supporting UK- and EU-based companies in all aspects of drug and device product lifecycle.
- SFL’s EU office can support UK-based companies to establish their presence and products in the EU and comply with EU regulations
- SFL’s UK office can support EU-based companies in submitting applications to MHRA to support the licensing and marketing of their drugs and devices
Contact us at email@example.com to arrange a call to discuss how SFL can support your company to prepare for changes after the transition period.